Australia · Series B startup

Who invested in OccuRx

2 rounds we have observed, with the 5 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Pharma

Funding summaryUpdated 26 Oct 2026

$20Mraised across 2 rounds since 2015, from 2 sources

$5.2MVenture$15MSeries B
Latest round
Series B, $15MSept 2022
Step-upi
2.8×
Investors
5
See who backed them

The funding story

Each circle is a round, placed by date and sized by amount. The line above is the running total.

20152016201720182019202020212022
$5.2MVenture$15MSeries B
First round
Venture, $5.2M
May 2015
Biggest round
$15M
Series B · Sept 2022
Between rounds
7.3 years
from the last two

The rounds

  1. Sept 2022
    Series B$15M2 new1 returning

    Source recorded

  2. May 2015

Who was in which round

The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.

Everyone who backed them

Missing a round, or an investor who was in one? Tell us.

Quick answers about OccuRx

Who invested in OccuRx?

OccuRx's investors include Uniseed Ventures, iSeed, Brandon Capital, Brandon Capital Partners and Medical Research Commercialisation Fund (MRCF).

How much has OccuRx raised?

OccuRx has raised $20M across 2 rounds since 2015.

When did OccuRx last raise?

OccuRx's most recent round was a Series B of $15M in Sept 2022.

What was OccuRx's biggest round?

Its most recent round, $15M in Sept 2022, is also its largest on record.

Who backed OccuRx first?

OccuRx's first round on record, in May 2015, was backed by Uniseed Ventures, Brandon Capital Partners and Medical Research Commercialisation Fund (MRCF).

What stage is OccuRx at?

OccuRx's latest named round is a Series B, in Sept 2022.

Where is OccuRx based?

OccuRx is based in Australia.

Companies like OccuRx

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.